702 / 1542
Rusthoven
JCO 2009
Hof
Strahl Onk 2007
Hoyer
Acta Oncol 2006
Nuyttens
IJROBP 2015
Study
Phase I/II
Phase I/II
Phase II
Phase II
Inclusion
≤ 3 lesions,
cum diam max 7cm
Extrathoracic
disease allowed if
low burden…
Max 4 cm
No other M+ site
Inoperable
Max 6 cm
Lung & liver
Inoperable
1-4 mets
Primary tu treated
Max 2 organs, 5
lesions,
Metachronous,
Primary controlled
…
Dose
48-60 Gy / 3fr
12-30 Gy / 1 fr
(isocenter dose)
45 Gy / 3 fr
30 Gy /1 fr
60 Gy / 3 fr or 5 fr
56 Gy / 7 fr
Pts/lesions
38/63
61/71
65/142
37/57
Toxicity grade 3 8% (3 pts)
5% (3 pts)
5 pts
Median fup
15.4 months
14 months
4.3 years
36 months
2 y Local Control
96%
74%
86%
90% (3-7 fr)
75% (1 fr)
2 y OS
39%
65%
38%
63%
Primary
various
various
colorectal
Various (colorectal)
Lung metastasis
Clinical indications
35